Corcept Therapeutics (CORT) reported $761M in revenue for fiscal 2025, +12.8% year on year. That ranks #1947 by revenue among 2853 SEC filers and #184 in Healthcare. Net income was $99.7M, a net margin of 13.1%. Revenue has grown 28.2% a year on average since 2016 ($81.3M then). The fiscal 2025 balance sheet shows $837M in total assets, $120M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $761M | +12.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $44.8M | −67.3% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $99.7M | −29.4% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $142M | −28.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $211,000 | −90.3% | FY20252025-12-31 |
| Total assetsAssets | $837M | −0.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $648M | −4.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $120M | −5.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | $0 | FY20172017-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $165M | −$31.8M | Open → |
| Q2 20262026-06-30 | $256M | $43.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Corcept Therapeutics Inc
- Ticker
- CORT
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001088856
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
| Emergent BiosolutionsEBS | $743M | $52.6M |
| RepligenRGEN | $738M | $48.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Corcept Therapeutics — Key figures |url=https://companiesranked.com/en/company/corcept-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Corcept Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/corcept-therapeuticsBibTeX
@misc{companiesranked-en-company-corcept-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Corcept Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/corcept-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-011091 · February 24, 2026
{{cite web |title=Corcept Therapeutics — Key figures — 10-K (0001628280-26-011091) |url=https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.